JP2022528840A - 安定性が増加した修飾オリゴヌクレオチド - Google Patents

安定性が増加した修飾オリゴヌクレオチド Download PDF

Info

Publication number
JP2022528840A
JP2022528840A JP2021557374A JP2021557374A JP2022528840A JP 2022528840 A JP2022528840 A JP 2022528840A JP 2021557374 A JP2021557374 A JP 2021557374A JP 2021557374 A JP2021557374 A JP 2021557374A JP 2022528840 A JP2022528840 A JP 2022528840A
Authority
JP
Japan
Prior art keywords
modified
binding
sirna
subunits
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021557374A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022528840A5 (enExample
Inventor
コボロバ，アナスタシア
モーリス ルネ ジャン ルー，ロイク
ヤマダ，ケン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Massachusetts Amherst
Original Assignee
University of Massachusetts Amherst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Massachusetts Amherst filed Critical University of Massachusetts Amherst
Publication of JP2022528840A publication Critical patent/JP2022528840A/ja
Publication of JP2022528840A5 publication Critical patent/JP2022528840A5/ja
Priority to JP2025015181A priority Critical patent/JP2025072451A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/533—Physical structure partially self-complementary or closed having a mismatch or nick in at least one of the strands
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/34—Allele or polymorphism specific uses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2021557374A 2019-03-26 2020-03-26 安定性が増加した修飾オリゴヌクレオチド Pending JP2022528840A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025015181A JP2025072451A (ja) 2019-03-26 2025-01-31 安定性が増加した修飾オリゴヌクレオチド

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962824136P 2019-03-26 2019-03-26
US62/824,136 2019-03-26
US201962826454P 2019-03-29 2019-03-29
US62/826,454 2019-03-29
US201962864792P 2019-06-21 2019-06-21
US62/864,792 2019-06-21
PCT/US2020/025017 WO2020198509A2 (en) 2019-03-26 2020-03-26 Modified oligonucleotides with increased stability

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025015181A Division JP2025072451A (ja) 2019-03-26 2025-01-31 安定性が増加した修飾オリゴヌクレオチド

Publications (2)

Publication Number Publication Date
JP2022528840A true JP2022528840A (ja) 2022-06-16
JP2022528840A5 JP2022528840A5 (enExample) 2023-04-03

Family

ID=72609530

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021557374A Pending JP2022528840A (ja) 2019-03-26 2020-03-26 安定性が増加した修飾オリゴヌクレオチド
JP2025015181A Pending JP2025072451A (ja) 2019-03-26 2025-01-31 安定性が増加した修飾オリゴヌクレオチド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025015181A Pending JP2025072451A (ja) 2019-03-26 2025-01-31 安定性が増加した修飾オリゴヌクレオチド

Country Status (4)

Country Link
US (2) US11820985B2 (enExample)
EP (1) EP3946369A4 (enExample)
JP (2) JP2022528840A (enExample)
WO (1) WO2020198509A2 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3929293A3 (en) 2015-04-03 2022-03-16 University Of Massachusetts Fully stabilized asymmetric sirna
WO2017030973A1 (en) 2015-08-14 2017-02-23 University Of Massachusetts Bioactive conjugates for oligonucleotide delivery
WO2017132669A1 (en) 2016-01-31 2017-08-03 University Of Massachusetts Branched oligonucleotides
WO2018031933A2 (en) 2016-08-12 2018-02-15 University Of Massachusetts Conjugated oligonucleotides
CN106987604B (zh) * 2017-03-29 2021-05-28 北京希诺谷生物科技有限公司 一种制备动脉粥样硬化疾病模型犬的方法
WO2018237245A1 (en) 2017-06-23 2018-12-27 University Of Massachusetts TWO TAIL SELF-ADMINISTRATION SIRNA AND ASSOCIATED METHODS
EP3781677A4 (en) 2018-04-16 2022-01-19 University of Massachusetts COMPOSITIONS AND METHODS FOR IMPROVED GENE EDITTING
BR112021002440A2 (pt) 2018-08-10 2021-05-04 University Of Massachusetts oligonucleotídeos modificados visando snps
WO2020041769A1 (en) 2018-08-23 2020-02-27 University Of Massachusetts O-methyl rich fully stabilized oligonucleotides
CN113614232A (zh) 2019-01-18 2021-11-05 马萨诸塞大学 动态药代动力学修饰锚
EP3946369A4 (en) 2019-03-26 2023-10-18 University Of Massachusetts MODIFIED OLIGONUCLEOTIDES WITH INCREASED STABILITY
KR20220047989A (ko) 2019-08-09 2022-04-19 유니버시티 오브 매사추세츠 Snp를 표적화하는 화학적으로 변형된 올리고뉴클레오타이드
US12365894B2 (en) 2019-09-16 2025-07-22 University Of Massachusetts Branched lipid conjugates of siRNA for specific tissue delivery
US12339155B2 (en) 2020-03-25 2025-06-24 Kuwana Metals, Ltd. Sensor
AU2021244600A1 (en) 2020-03-26 2022-11-03 University Of Massachusetts Synthesis of modified oligonucleotides with increased stability
CA3174079A1 (en) 2020-05-26 2021-12-02 Anastasia Khvorova Synthetic oligonucleotides having regions of block and cluster modifications
EP4158028A4 (en) 2020-05-28 2024-10-02 University Of Massachusetts OLIGONUCLEOTIDES FOR THE MODULATION OF SARS-COV-2
BR112023019981A2 (pt) 2021-03-29 2023-12-12 Alnylam Pharmaceuticals Inc Composições do agente irna de huntingtina (htt) e métodos de uso das mesmas
IL309334A (en) 2021-06-23 2024-02-01 Univ Massachusetts Anti-FLT1 optimized oligonucleotide compounds for the treatment of preeclampsia and other angiogenic disorders
US20240425853A1 (en) * 2021-07-22 2024-12-26 Microbio (Shanghai) Co. Ltd. Modified small interfering rna molecules with reduced off-target effects
CN115819484B (zh) * 2021-07-23 2026-06-02 苏州瑞博生物技术股份有限公司 双链寡核苷酸、含双链寡核苷酸的组合物与缀合物及制备方法和用途
WO2023069495A1 (en) * 2021-10-19 2023-04-27 Alnylam Pharmaceuticals, Inc. Oligonucleotides with 2'-deoxy-2'-f-2'-c-methyl nucleotides
WO2023081908A2 (en) 2021-11-08 2023-05-11 University Of Massachusetts Oligonucleotides for sod1 modulation
WO2023114989A2 (en) * 2021-12-17 2023-06-22 University Of Massachusetts Oligonucleotides for mlh3 modulation
US20240052344A1 (en) * 2022-05-04 2024-02-15 University Of Massachusetts Oligonucleotides for pms1 modulation
CN119487046B (zh) * 2022-06-27 2026-08-07 大睿生物医药科技(上海)有限公司 含有可降低脱靶毒性的核苷酸类似物的双链rna
WO2025264952A2 (en) * 2024-06-21 2025-12-26 Eli Lilly And Company Novel rna therapeutics and uses thereof
WO2026006109A2 (en) * 2024-06-24 2026-01-02 Eli Lilly And Company Novel rna therapeutics and uses thereof
WO2026080452A1 (en) * 2024-10-07 2026-04-16 Creyon Bio, Inc. Fluorosulfonyl phosphoramidate (fsp) backbone modification and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010033247A2 (en) * 2008-09-22 2010-03-25 Rxi Pharmaceuticals Corporation Reduced size self-delivering rnai compounds
JP2018516091A (ja) * 2015-04-03 2018-06-21 ユニバーシティ・オブ・マサチューセッツＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｍａｓｓａｃｈｕｓｅｔｔｓ ハンチンチンｍＲＮＡをターゲティングするオリゴヌクレオチド化合物

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5610289A (en) 1990-07-27 1997-03-11 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogues
US5672697A (en) * 1991-02-08 1997-09-30 Gilead Sciences, Inc. Nucleoside 5'-methylene phosphonates
JPH0641183A (ja) 1992-07-23 1994-02-15 Mitsubishi Kasei Corp オリゴヌクレオチド単分子膜
US6291438B1 (en) 1993-02-24 2001-09-18 Jui H. Wang Antiviral anticancer poly-substituted phenyl derivatized oligoribonucleotides and methods for their use
EP0691979A1 (en) 1993-03-31 1996-01-17 Sanofi Novel 5'-substituted nucleosides and oligomers produced therefrom
WO1996003500A1 (en) 1994-07-26 1996-02-08 Ltt Institute Co., Ltd. Sustance with antiviral activity
US6025335A (en) 1995-09-21 2000-02-15 Lipitek International, Inc. L-Nucleoside Dimer Compounds and therapeutic uses
US6242589B1 (en) * 1998-07-14 2001-06-05 Isis Pharmaceuticals, Inc. Phosphorothioate oligonucleotides having modified internucleoside linkages
US20100240730A1 (en) * 2002-02-20 2010-09-23 Merck Sharp And Dohme Corp. RNA Interference Mediated Inhibition of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid (siNA)
EP1578754A4 (en) 2002-10-30 2006-07-19 Makscientific Llc ROTARY PHOSPHOLIPIDS SUBSTITUTED ANTIPROTOZOOSES
DE10326302A1 (de) 2003-06-11 2004-12-30 Gnothis Holding Sa Bi-Fluorophor-markierte Sonden zum Nachweis von Nukleinsäuren
US20050176045A1 (en) 2004-02-06 2005-08-11 Dharmacon, Inc. SNP discriminatory siRNA
JP2008504840A (ja) 2004-06-30 2008-02-21 アルニラム ファーマスーティカルズ インコーポレイテッド 非リン酸骨格結合を含むオリゴヌクレオチド
US8309356B2 (en) 2009-04-01 2012-11-13 Yale University Pseudocomplementary oligonucleotides for targeted gene therapy
US8987222B2 (en) 2009-04-08 2015-03-24 University Of Massachusetts Single nucleotide polymorphism (SNP) targeting therapies for the treatment of huntington'S disease
ES2733708T3 (es) 2010-02-08 2019-12-02 Ionis Pharmaceuticals Inc Reducción selectiva de variantes alélicas
WO2011125943A1 (ja) 2010-04-01 2011-10-13 日本新薬株式会社 修飾オリゴヌクレオチド
JP2013545817A (ja) 2010-12-16 2013-12-26 バーテックス ファーマシューティカルズ インコーポレイテッド インフルエンザウイルス複製阻害物質
AU2011343647A1 (en) 2010-12-16 2013-05-02 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
RU2013132681A (ru) 2010-12-16 2015-01-27 Вертекс Фармасьютикалз Инкорпорейтед Ингибиторы репликации вирусов гриппа
GB201105137D0 (en) 2011-03-28 2011-05-11 Isis Innovation Therapeutic molecules for use in the suppression of Parkinson's disease
WO2012143796A2 (en) 2011-04-21 2012-10-26 Institut Pasteur Korea Anti-inflammation compounds
EP3007705A4 (en) 2013-06-12 2017-02-15 Oncoimmunin, Inc. Systemic in vivo delivery of oligonucleotides
CA2938084A1 (en) 2014-01-27 2015-07-30 The Board Of Trustees Of The Leland Stanford Junior University Oligonucleotides and methods for treatment of cardiomyopathy using rna interference
EP3137606A4 (en) 2014-05-01 2018-04-25 Larry J. Smith METHODS AND MODIFICATIONS THAT PRODUCE ssRNAi COMPOUNDS WITH ENHANCED ACTIVITY, POTENCY AND DURATION OF EFFECT
WO2017132669A1 (en) * 2016-01-31 2017-08-03 University Of Massachusetts Branched oligonucleotides
WO2018041973A1 (en) 2016-09-01 2018-03-08 Proqr Therapeutics Ii B.V. Chemically modified single-stranded rna-editing oligonucleotides
US11603532B2 (en) 2017-06-02 2023-03-14 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
BR112021002440A2 (pt) 2018-08-10 2021-05-04 University Of Massachusetts oligonucleotídeos modificados visando snps
EP3946369A4 (en) 2019-03-26 2023-10-18 University Of Massachusetts MODIFIED OLIGONUCLEOTIDES WITH INCREASED STABILITY
CN115605226A (zh) 2020-03-26 2023-01-13 纽特莱特公司（Us） 具有抗炎和生长促进活性的去乙酰基葡糖胺胞壁酰二肽的亲脂对映异构体
AU2021244600A1 (en) 2020-03-26 2022-11-03 University Of Massachusetts Synthesis of modified oligonucleotides with increased stability

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010033247A2 (en) * 2008-09-22 2010-03-25 Rxi Pharmaceuticals Corporation Reduced size self-delivering rnai compounds
JP2018516091A (ja) * 2015-04-03 2018-06-21 ユニバーシティ・オブ・マサチューセッツＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｍａｓｓａｃｈｕｓｅｔｔｓ ハンチンチンｍＲＮＡをターゲティングするオリゴヌクレオチド化合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MOLECULAR THERAPY-NUCLEIC ACIDS, vol. 4, no. 12, JPN5018004887, 1 December 2015 (2015-12-01), pages 266 - 1, ISSN: 0005285953 *

Also Published As

Publication number Publication date
US11820985B2 (en) 2023-11-21
EP3946369A4 (en) 2023-10-18
JP2025072451A (ja) 2025-05-09
US20200385740A1 (en) 2020-12-10
EP3946369A2 (en) 2022-02-09
WO2020198509A3 (en) 2020-11-05
WO2020198509A2 (en) 2020-10-01
US20240141362A1 (en) 2024-05-02

Similar Documents

Publication Publication Date Title
US20240141362A1 (en) Modified oligonucleotides with increased stability
CN115666659B (zh) 稳定性增加的修饰的寡核苷酸的合成
US20240132892A1 (en) OLIGONUCLEOTIDE-BASED MODULATION OF C9orf72
JP7687685B2 (ja) 組織特異的なａｐｏｅ調節のためのオリゴヌクレオチド
JP2023518439A (ja) Ｍａｐｔ調節のためのオリゴヌクレオチド
US20210355491A1 (en) Oligonucleotides for msh3 modulation
US20230392146A1 (en) Oligonucleotides for app modulation
US20220090069A1 (en) Oligonucleotides for htt-1a modulation
US20230313198A1 (en) Oligonucleotides for mlh3 modulation
JP2021533762A (ja) Ｓｎｐを標的化する修飾オリゴヌクレオチド
WO2021242883A1 (en) Synthetic oligonucleotides having regions of block and cluster modifications
US20250043284A1 (en) Oligonucleotides for snca modulation
EP4125930A1 (en) Dual-acting sirna based modulation of c9orf72
EP4110913A2 (en) Oligonucleotides for prnp modulation
WO2023014654A2 (en) Oligonucleotides for htt-1a modulation
US20240309372A1 (en) Stabilization of oligonucleotide and oligonucleotide-protein complex using alkylated phosphate

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230323

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230323

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240319

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240618

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241001